bioAffinity Technologies Inc
BIAF
NASDAQ
Biotechnology
$0.40
USD
+0.02 (+4.99%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $3.10M
Volume 454.3K
Revenue
$5.90M
TTM
-23.2%
YoY
Gross Margin
69%
TTM
+12.9%
YoY
Net Income
$-15.19M
TTM
-29.9%
YoY
Operating Cash Flow
$-11.47M
TTM
-49.4%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 1.3 | 1.4 | 1.6 | 1.4 | 1.5 |
YoY Growth | -47.1% | -38.5% | -27.8% | -27.1% | +19.0% |
Cost of Revenue | 0.0 | 0.9 | 0.9 | 0.0 | 0.0 |
Gross Profit | 1.3 | 0.5 | 0.7 | 1.4 | 1.5 |
Selling, General & Administrative | 2.2 | 2.2 | 3.0 | 3.2 | 2.9 |
Other Operating Expenses | 1.0 | 0.0 | 0.0 | 0.9 | 1.1 |
Total Operating Expenses | 3.8 | 2.8 | 3.8 | 5.0 | 4.8 |
Operating Income | -2.5 | -2.3 | -3.1 | -3.6 | -3.3 |
EBITDA | -2.4 | -2.2 | -3.0 | -3.5 | -3.3 |
Other Income / Expense | -1.5 | -2.8 | -0.0 | -0.0 | -0.0 |
Total Other Income / Expense | -1.5 | -2.8 | 0.0 | -0.0 | -0.0 |
Income Before Income Taxes | -4.0 | -5.0 | -3.1 | -3.6 | -3.4 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -4.1 | -5.1 | -3.1 | -3.6 | -3.4 |
Consolidated Net Income / Loss | -4.1 | -5.1 | -3.1 | -3.6 | -3.4 |
Net Income Attributable to Common Shareholders | -4.1 | -5.1 | -3.1 | -3.6 | -3.4 |
Basic EPS | -$5.07 | -$4.74 | $0.00 | -$0.81 | -$0.64 |
Diluted EPS | -$5.07 | -$4.74 | $0.00 | -$0.81 | -$0.64 |
Basic Shares Outstanding | 0.8M | 1.1M | 0.0M | 4.5M | 5.2M |
Diluted Shares Outstanding | 0.8M | 1.1M | 0.0M | 4.5M | 5.2M |